+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.

Age: 18Years - 50YearsFEMALEPhase 3
120 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness of switching to the study drugs GS-3242 combined with Lenacapavir LEN compared to continuing the standard treatment Biktarvy bictegraviremtricitabinetenofovir alafenamide, BFTAF in adults with HIV-1 infection who are virologically suppressed. This Phase 2 randomized study aims to assess the safety and efficacy of an injectable regimen of GS-3242 plus LEN versus oral BFTAF in different treatment groups over distinct time points, with Part A focusing on Week 35 and Part B on Week 26. Participants are randomly assigned to receive either oral loading doses of GS-3242 and LEN tablets followed by intramuscular IM injections of these drugs for up to 52 weeks, or to continue daily oral BFTAF for the same duration. Different dosing regimens of GS-3242 and LEN are used across groups, with some groups receiving different IM doses. The study includes both randomized and non-randomized groups across the two parts. During the study, participants will be monitored for viral load, specifically HIV-1 RNA levels, using the US FDA Snapshot Algorithm at Weeks 26, 35, and 52, as well as CD4 cell counts. Safety is assessed by recording treatment-emergent adverse events throughout the study period. Drug concentrations are also measured at specific weeks to evaluate pharmacokinetics. The total participant involvement can last up to 52 weeks, with regular assessments to evaluate treatment efficacy and safety.

Age: 18Years +All GendersPhase 2
57 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are investigating whether a modified version of metaxalone 640 mg can reduce pain in adults experiencing acute low back and leg pain associated with lumbar spinal stenosis and sciatica. This phase 4, double-blind, randomized, placebo-controlled trial compares the effects of metaxalone plus standard care to a placebo in patients aged 18 to 80 years who are otherwise healthy and have newly occurring pain. Participants will be randomly assigned to one of two groups one receiving metaxalone 640 mg oral tablets every 6 hours for 7 days, and the other receiving an inactive placebo capsule on the same schedule. The study is conducted across multiple centers with a parallel design and includes a pilot phase followed by a larger randomized study. During the trial, participants will complete surveys on Day 1 before treatment and again on Day 7 to report on pain intensity, the impact of pain on physical activity, and sleep interference. The primary outcome measure is the change in the Numeric Pain Scale score from Day 1 to Day 7. Participants will be monitored for adherence and safety throughout the 7-day treatment period.

Age: 18Years - 80YearsAll GendersPhase 4
24 locations
C

Actively Recruiting

Researchers are evaluating how well a long-acting injectable combination treatment of lenacapavir, teropavimab, and zinlirvimab works compared to continuing daily oral HIV treatment in adults with HIV-1 who already have their virus well controlled. The study focuses on virologically suppressed people with HIV-1 and aims to measure how many participants maintain viral suppression after one year of treatment. Participants in one group will receive an initial dose of oral and injectable lenacapavir along with intravenous infusions of teropavimab and zinlirvimab on Day 1, followed by self-administered oral lenacapavir on Day 2. Every 26 weeks, they will receive additional injections and infusions up to Week 92, with an option to continue in an extension phase. The other group will continue their stable oral antiretroviral therapy as prescribed, also with an option to switch to the injectable combination after Week 92. Throughout the study, participants will be monitored for viral load levels at Weeks 52 and 92 using FDA-approved methods, changes in CD4 T-cell counts, and the presence of antibodies against study drugs. Safety will be assessed by tracking adverse events and treatment discontinuations. Drug levels will also be measured at several timepoints. The study may last until March 2033, including the extension phase for those who continue treatment.

Age: 18Years +All GendersPhase 3
2 locations
E

Actively Recruiting

Researchers are evaluating a new long-acting injectable treatment combining lenacapavir LEN, teropavimab TAB, and zinlirvimab ZAB compared to injections of cabotegravir CAB and rilpivirine RPV given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment. The study aims to determine which regimen better maintains viral suppression after one year 52 weeks of treatment. Participants will be randomly assigned to one of two groups. One group receives oral LEN on Day 1, subcutaneous LEN and intravenous infusions of TAB and ZAB on Day 1, then oral LEN on Day 2, followed by subcutaneous LEN and IV infusions of TAB and ZAB every 26 weeks up to Week 92. The other group discontinues their current oral therapy and receives intramuscular injections of CAB and RPV on Day 1, Week 4, and then every 8 weeks up to Week 92. After Week 92, eligible participants may continue LEN TAB ZAB in an extension phase until its completion or discontinuation. During the study, participants will undergo regular monitoring of their HIV-1 RNA levels to assess viral suppression, along with measurements of CD4 T-cell counts. Safety is tracked through adverse event reports and blood tests. The primary outcome is the proportion of participants with HIV-1 RNA at or above 50 copiesmL at Week 52. Secondary outcomes include viral load at Week 92, immune cell changes, drug concentration levels, and antibody development. The total study duration extends up to approximately seven years, including follow-up and extension phases.

Age: 18Years +All GendersPhase 3
19 locations